ArticleFrontiers in immunology2026
Age at onset distinguishes clinical features and relapse risk in autoimmune glial fibrillary acidic protein astrocytopathy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Age is a critical factor influencing the clinical presentation of neuroimmunological diseases. This study aimed to investigate the different clinical characteristics of early-onset autoimmune glial fibrillary acidic protein astrocytopathy (EO-GFAP-A age < 45 years) and late-onset group(LO-GFAP-A age ≥ 45 years) (GFAP-A), and to preliminarily explore the correlation between age and relapse. Methods: We retrospectively enrolled 69 patients with first-onset GFAP-A who were admitted to the First Affiliated Hospital of Zhengzhou University from January 2020 to January 2025. All patients were followed-up for more than one year. We performed univariate analysis to compare clinical data between the two groups. Additionally, Kaplan-Meier survival analysis (with Log-rank test) and univariate Cox regression model were utilized to preliminarily assess the correlation between age and recurrence. Results: The proportions of patients with headache, fever, psychosis, and meningeal irritation signs were significantly higher in the EO-GFAP-A group than in the LO-GFAP-A group ( Conclusion: Patients with EO-GFAP-A and LO-GFAP-A exhibit distinct clinical characteristics, and age is suggested to be a potential risk factor for relapse. Consequently, more aggressive therapeutic interventions and individualized long-term management strategies are warranted for LO-GFAP-A patients to mitigate the risk of disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.